Navigation Links
UMass Boston's Venture Development Center Announces New Bio-Science Partner

Pressure BioSciences Inc. to Join University's R&D Facility

Boston, MA (Vocus) January 21, 2010 -- The University of Massachusetts Boston today announced that South Easton-based Pressure BioSciences Inc., (PBI) a developer of bench-top sample preparation instruments, has moved its research and development operations to the university's Venture Development Center. PBI develops and markets pressure cycling technology that enables safe, rapid, and reproducible extraction of proteins, DNA, RNA, and small molecules from biological samples for biochemical analysis.

This brings the 18,000-square-foot business incubator to 75 percent occupancy since opening in May 2009.

The addition of PBI is expected to greatly benefit the Center for Personalized Cancer Therapy, a joint UMass Boston venture with the Dana-Farber/Harvard Cancer Center to be launched within the VDC. The purpose of the CPCT is to conduct basic and translational research to develop low-cost diagnostic tests focusing on cancers that vary at the molecular level but remain indistinguishable in conventional clinical analyses.

“Our scientists connected with the Center for Personalized Cancer Therapy are excited about collaborating with PBI," said William Brah, executive director of the VDC. “The goals of CPCT are ideally complemented by the cutting-edge, PCT-based sample preparation technology developed by PBI, which can permit tumor biomarkers in ordinary clinical preparations to be more rapidly and effectively analyzed.”

UMass Boston has purchased PBI's Barocycler instrument, which offers shorter processing time, higher throughput, and reduced operating costs, all without sacrificing quality. The instrument will be available to UMass Boston scientists and students to enhance their research and training, and will also provide CPCT with an important tool for its translational research.

PBI, a publicly traded company (PBIO), began commercializing pressure cycling technology in 2005. It recently raised approximately $1.2 million to support on-going efforts to increase sales and applications for PCT. PBI currently has about 90 instrument installations worldwide.

In addition to Pressure BioSciences Inc., the VDC is home to:

  • DPixel, a management consulting company specialized in seed and early stage investments.
  • Anthurium Solutions, Inc., a software company building a platform for matching continuous digital work with virtual workers globally.
  • Symmetric Computing, a startup company commercializing advanced supercomputing technology.
  •, a technology-powered provider of retirement planning and investment management services.
  • GeoMed Analytical, a full service analytical testing and development laboratory.
  • Developmental Sciences Research Center/HORIZON, a translational research center focused on the study of community health.
  • Collaborative Institute for Oceans, Climate, and Security, a center focused on the security of living environments and global coastal communities.

About the Venture Development Center
The Venture Development Center is a research and development center and business incubator for entrepreneurs from within and outside UMass Boston. The center is designed to accelerate time to investment and market, while keeping costs to a minimum. The VDC offers short-term, ready-to-use offices and laboratories with managed services that meet the needs of startups. The VDC offers the ability to foster collaboration with the intellectual resources of UMass Boston's faculty, staff, and students. To learn more about the VDC, visit

About the University of Massachusetts Boston
With a growing reputation for innovative research addressing complex issues, the University of Massachusetts Boston, metropolitan Boston's only public university, offers its diverse student population both an intimate learning environment and the rich experience of a great American city. UMass Boston's seven colleges and graduate schools serve more than 14,000 students while engaging local, national, and international constituents through academic programs, research centers, and public service activities. To learn more about UMass Boston, visit

DeWayne Lehman, 617 287-5302
William Brah, 617 287-7723

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. UMass Boston Opens Venture Development Center to Expand R&D Activity
2. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
3. Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution
4. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
5. Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada
6. Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean.
7. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
8. Kansas Bioscience Authority Commits $50 Million to Increase Venture Capital, Accelerate Bioscience Business Growth
9. Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards
10. Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards
11. RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Post Your Comments:
Related Image:
UMass Boston's Venture Development Center Announces New Bio-Science Partner
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):